We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

87 hedge funds and large institutions have $345M invested in Iovance Biotherapeutics in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

6% less funds holding

Funds holding: 93 → 87 (-6)

11% less capital invested

Capital invested by funds: $387M → $345M (-$41.9M)

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

32% less call options, than puts

Call options by funds: $2.05M | Put options by funds: $3.02M

Holders
87
Holders Change
-6
Holders Change %
-6.45%
% of All Funds
2.17%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
11
Increased
38
Reduced
20
Closed
16
Calls
$2.05M
Puts
$3.02M
Net Calls
-$969K
Net Calls Change
+$5.91M

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$20.9M
2
ACP
Acuta Capital Partners
California
+$3.99M
3
BFA
BlackRock Fund Advisors
California
+$2.88M
4
ACA
Avoro Capital Advisors
New York
+$1.81M
5
GTC
Ghost Tree Capital
New York
+$1.03M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.46M
2
CAM
Cormorant Asset Management
Massachusetts
-$4.16M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.96M
4
QF
QVT Financial
New York
-$1.74M
5
OAM
Oxford Asset Management
United Kingdom
-$1.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$1.36M +$72.1K +10,483 +6%
Allianz Asset Management
27
Allianz Asset Management
Germany
$1.34M -$191K -27,707 -13%
Morgan Stanley
28
Morgan Stanley
New York
$1.23M +$1.02M +148,279 +523%
UBS Group
29
UBS Group
Switzerland
$1.13M -$896K -130,238 -44%
First Eagle Investment Management
30
First Eagle Investment Management
New York
$1.04M – – –
TCIM
31
TIAA CREF Investment Management
New York
$1.04M -$28.2K -4,095 -3%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$876K +$867K +126,015 New
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$807K +$25.5K +3,700 +3%
VIA
34
Vident Investment Advisory
Georgia
$727K +$118K +17,220 +20%
OAM
35
Oxford Asset Management
United Kingdom
$696K -$1.56M -227,251 -69%
Millennium Management
36
Millennium Management
New York
$659K +$653K +94,828 New
TA
37
Teachers Advisors
New York
$580K +$27.7K +4,025 +5%
Swiss National Bank
38
Swiss National Bank
Switzerland
$518K – – –
Goldman Sachs
39
Goldman Sachs
New York
$392K -$83.6K -12,144 -18%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$391K +$48.4K +7,033 +14%
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$354K – – –
ProShare Advisors
42
ProShare Advisors
Maryland
$348K +$54.6K +7,928 +19%
CIBC Private Wealth Group
43
CIBC Private Wealth Group
Georgia
$299K – – –
Deutsche Bank
44
Deutsche Bank
Germany
$297K +$1.51K +220 +0.5%
Citigroup
45
Citigroup
New York
$291K +$187K +27,242 +185%
Citadel Advisors
46
Citadel Advisors
Florida
$283K -$41.2K -5,984 -13%
AllianceBernstein
47
AllianceBernstein
Tennessee
$275K – – –
OPPM
48
Opus Point Partners Management
New York
$271K +$106K +15,353 +65%
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$269K +$27.2K +3,954 +11%
Wells Fargo
50
Wells Fargo
California
$265K +$131K +18,980 +99%
1
2
3 4 5

IOVA Hedge Fund Activity: Q4 2016 in Review

87 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2016, worth a combined $345M — down 11% from $387M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of IOVA and 11 opened new positions — a net loss of 5 holders — while 20 trimmed existing stakes and 38 added.

The largest buyer was Franklin Resources, adding an estimated $20.9M. The largest seller was Fidelity Investments, cutting an estimated $7.46M.

  • 87 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2016, down from 93 in Q3 2016.
  • Funds reported $345M of Iovance Biotherapeutics stock for Q4 2016, down 11% quarter-over-quarter.
  • 11 funds opened new Iovance Biotherapeutics positions in Q4 2016 and 16 closed out, a net change of -5 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2016 was Franklin Resources, an estimated $20.9M added.
  • The largest Iovance Biotherapeutics seller in Q4 2016 was Fidelity Investments, an estimated $7.46M sold.

Based on aggregated 13F filings for Q4 2016.